Table 1. Previous reported cases of stage I ovarian angiosarcoma.

Author	Year	Age	Initial surgery	Adjuvant systemic therapy	Recurrence	Treatment for recurrence	Status	Survival duration from diagnosis (months)
Lifschitz-Mercer et al.20)	1998	25	USO	Ifosfamide, doxorubicin	+ (18 months)	NA	Alive	18
Furihata et al.18)	1998	46	TAH + BSO + PLND	Cisplatin, RT	+ (4 months)	Chemotherapy	DOD	9
Nucci et al.21)	1998	27	USO	—	—	—	NED	14
Nucci et al.21)	1998	42	USO	NA	NA	NA	DOD	<24
Quesenberry et al.22)	2005	31	TAH + BSO	MAID	—	—	NED	10
Bösmüller et al.23)	2011	81	TAH + USO (post-USO)	Doxorubicin	—	—	NED	11
Pariury et al.2)	2019	11	USO	—	+ (6 months)	Chemotherapy CRS + HIPEC	Alive	39
Ye et al.7)	2021	47	TAH + BSO + PLND	Olaparib, immunotherapy, RT	—	—	NED	9
Zhou et al.19)	2023	41	TAH + BSO	MAID	+ (3 months)	Chemotherapy Immunotherapy	Alive	27
Johnson and Argenta10)	2023	29	BSO (post-TAH)	Olaparib	—	—	NED	20
Matsumoto (our case)	2026	14	USO	—	+ (6 months)	CRS chemotherapy, RT	Alive	12

BSO, bilateral salpingo-oophorectomy; CRS, cytoreductive surgery; DOD, dead of disease; HIPEC, hyperthermic intraperitoneal chemotherapy; MAID, mesna, doxorubicin, ifosfamide and dacarbazine; NA, not available; NED, no evidence of disease; PLND, pelvic lymph node dissection; RT, radiotherapy; TAH, total abdominal hysterectomy; USO, unilateral salpingo-oophorectomy